{
    "Trade/Device Name(s)": [
        "Amphetamines II",
        "ONLINE DAT II Amphetamines II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K083764",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983699",
        "K012998"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "LAF"
    ],
    "Summary Letter Date": "December 2, 2009",
    "Summary Letter Received Date": "December 3, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3100"
    ],
    "Regulation Name(s)": [
        "Enzyme Immunoassay, Amphetamine"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi 917 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "KIMS (Kinetic Interaction of Microparticles in Solution)",
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "KIMS",
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent system"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Amphetamines II in vitro diagnostic assay for amphetamines/methamphetamines detection using KIMS methodology on automated analyzers",
    "Indications for Use Summary": "In vitro diagnostic test for qualitative and semiquantitative detection of amphetamines and methamphetamines in urine on automated clinical chemistry analyzers at cutoff concentrations of 300, 500, and 1000 ng/mL; intended for use with confirmatory methods such as GC/MS",
    "fda_folder": "Toxicology"
}